Physician profile
Heta D Patel
NPI 1316581028
$1,509.97
in general payments reported to CMS, 2019-2025
13 companies · $693 in 2025
The $693 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.63 · 2021: $14.31 · 2022: $69.68 · 2023: $29.66 · 2024: $688 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $553.92 | 2024-2025 | |
| Harrow Eye, LLC | $286.97 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $140.94 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $122.83 | 2025 | |
| Alcon Vision LLC | $70.16 | 2023-2025 | Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $68.57 | 2022-2025 | Scoutpro Osmolarity System, Vyzulta, Miebo |
| Tarsus Pharmaceuticals, INC. | $54.26 | 2024-2025 | Xdemvy |
| Amgen INC. | $49.38 | 2025 | Tepezza |
| Dompe US, INC. | $37.45 | 2024-2025 | Oxervate |
| Janssen Biotech, INC. | $36.24 | 2024-2025 | Simponi, Stelara, Tremfya |
| Abbvie INC. | $34.42 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.94 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $25.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heta Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.